Polycomb and the emerging epigenetics of pancreatic cancer

Journal of Gastrointestinal Cancer

Volumn 42, Issue 2, 2011, Pages 100-111

  Grzenda, Adrienne ^a   Ordog, Tamas ^a   Urrutia, Raul ^a  

^a MAYO CLINIC   (United States)

Author keywords

Epigenetics; Pancreatic cancer; Polycomb; Polycomb repressive complex

Indexed keywords

3 DEAZANEPLANOCIN A; ANTINEOPLASTIC AGENT; BMI1 PROTEIN; DNA; DOXORUBICIN; GEMCITABINE; HISTONE; POLYCOMB GROUP PROTEIN; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; RING FINGER PROTEIN; RING1B PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER CELL DESTRUCTION; CANCER GROWTH; CANCER INVASION; CANCER RESEARCH; CANCER RESISTANCE; CELL DIFFERENTIATION; CHEMOSENSITIZATION; DNA METHYLATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HISTONE METHYLATION; HUMAN; NONHUMAN; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; REPRESSOR PROTEINS;

EID: 79956226771     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-011-9262-4     Document Type: Review

References (119)

1. A Jemal, et al. 2010 Cancer statistics CA Cancer J Clin 60 5 277 300 20610543 10.3322/caac.20073
2. Wang Z, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8(1):27-33.
3. RH Hruban, et al. 2001 Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions Am J Surg Pathol 25 5 579 586 11342768 10.1097/00000478-200105000-00003 1:STN:280:DC%2BD3M3ktV2kuw%3D%3D (Pubitemid 32423354)
4. S Jones, et al. 2008 Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 321 5897 1801 1806 18772397 10.1126/science.1164368 1:CAS:528:DC%2BD1cXhtFCrtLrL
5. RH Hruban NV Adsay 2009 Molecular classification of neoplasms of the pancreas Hum Pathol 40 5 612 623 19362631 10.1016/j.humpath.2009.01.008 1:CAS:528:DC%2BD1MXktl2isr8%3D
6. X Cheng RM Blumenthal 2008 Mammalian DNA methyltransferases: a structural perspective Structure 16 3 341 350 18334209 10.1016/j.str.2008.01.004 (Pubitemid 351324115)
7. F Antequera A Bird 1999 CpG islands as genomic footprints of promoters that are associated with replication origins Curr Biol 9 17 R661 R667 10508580 10.1016/S0960-9822(99)80418-7 1:CAS:528:DyaK1MXlvFWltbk%3D (Pubitemid 29442475)
8. M Schutte, et al. 1997 Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas Cancer Res 57 15 3126 3130 9242437 1:CAS:528:DyaK2sXkvFKru78%3D (Pubitemid 27351723)
9. C Rosty, et al. 2003 p16 Inactivation in pancreatic intraepithelial neoplasias (PanINs) arising in patients with chronic pancreatitis Am J Surg Pathol 27 12 1495 1501 14657708 10.1097/00000478-200312000-00001 (Pubitemid 37486610)
10. N Sato, et al. 2003 Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays Cancer Res 63 13 3735 3742 12839967 1:CAS:528:DC%2BD3sXltVGqsr0%3D (Pubitemid 36793060)
11. N Sato, et al. 2008 CpG island methylation profile of pancreatic intraepithelial neoplasia Mod Pathol 21 3 238 244 18157091 10.1038/modpathol. 3800991 1:CAS:528:DC%2BD1cXisVKmt70%3D (Pubitemid 351304281)
12. N Omura M Goggins 2009 Epigenetics and epigenetic alterations in pancreatic cancer Int J Clin Exp Pathol 2 4 310 326 19158989 1:CAS:528:DC%2BD1MXnslChtLs%3D
13. K Luger 2003 Structure and dynamic behavior of nucleosomes Curr Opin Genet Dev 13 2 127 135 12672489 10.1016/S0959-437X(03)00026-1 1:CAS:528:DC%2BD3sXisV2rtb4%3D (Pubitemid 36369736)
14. T Jenuwein CD Allis 2001 Translating the histone code Science 293 5532 1074 1080 11498575 10.1126/science.1063127 1:CAS:528:DC%2BD3MXmtVWltro%3D (Pubitemid 32758077)
15. Chi P, Allis CD, Wang GG. Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 10(7):457-69.
16. MJ Bottomley 2004 Structures of protein domains that create or recognize histone modifications EMBO Rep 5 5 464 469 15184976 10.1038/sj.embor.7400146 1:CAS:528:DC%2BD2cXks1Cmu7o%3D (Pubitemid 38745036)
17. S Maurer-Stroh, et al. 2003 The Tudor domain 'Royal Family': Tudor, plant Agenet, Chromo, PWWP and MBT domains Trends Biochem Sci 28 2 69 74 12575993 10.1016/S0968-0004(03)00004-5 1:CAS:528:DC%2BD3sXptlyhtQ%3D%3D (Pubitemid 36165134)
18. G Lomberk, et al. 2006 Evidence for the existence of an HP1-mediated subcode within the histone code Nat Cell Biol 8 4 407 415 16531993 10.1038/ncb1383 1:CAS:528:DC%2BD28Xjt12qs70%3D
19. B Mateescu, et al. 2004 Tethering of HP1 proteins to chromatin is relieved by phosphoacetylation of histone H3 EMBO Rep 5 5 490 496 15105826 10.1038/sj.embor.7400139 1:CAS:528:DC%2BD2cXks1Cmu7Y%3D (Pubitemid 38745040)
20. N Yamada, et al. 2008 MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells Cancer Res 68 8 2708 2716 18413738 10.1158/0008-5472.CAN-07-6844 1:CAS:528:DC%2BD1cXks1Gitb0%3D (Pubitemid 351556268)
21. GK Dialynas MW Vitalini LL Wallrath 2008 Linking heterochromatin protein 1 (HP1) to cancer progression Mutat Res 647 1-2 13 20 18926834 1:CAS:528:DC%2BD1cXhtlyks7nO
22. A Sparmann M van Lohuizen 2006 Polycomb silencers control cell fate, development and cancer Nat Rev Cancer 6 11 846 856 17060944 10.1038/nrc1991 1:CAS:528:DC%2BD28XhtFWhs7bE (Pubitemid 44629896)
23. Mills AA. Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer. 10(10):669-82.
24. M Ku, et al. 2008 Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains PLoS Genet 4 10 e1000242 18974828 10.1371/journal.pgen.1000242
25. R Cao, et al. 2002 Role of histone H3 lysine 27 methylation in Polycomb-group silencing Science 298 5595 1039 1043 12351676 10.1126/science.1076997 1:CAS:528:DC%2BD38Xot12rs7g%3D (Pubitemid 35247314)
26. B Czermin, et al. 2002 Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites Cell 111 2 185 196 12408863 10.1016/S0092-8674(02)00975-3 1:CAS:528: DC%2BD38Xotlahsr8%3D (Pubitemid 35292439)
27. T Jenuwein, et al. 1998 SET domain proteins modulate chromatin domains in eu- and heterochromatin Cell Mol Life Sci 54 1 80 93 9487389 10.1007/s000180050127 1:CAS:528:DyaK1cXns1CltA%3D%3D (Pubitemid 28048252)
28. A Kuzmichev, et al. 2002 Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein Genes Dev 16 22 2893 2905 12435631 10.1101/gad.1035902 1:CAS:528:DC%2BD38XovVejsLY%3D (Pubitemid 35334738)
29. R Cao Y Zhang 2004 SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex Mol Cell 15 1 57 67 15225548 10.1016/j.molcel.2004.06.020 1:CAS:528: DC%2BD2cXlvFejurc%3D (Pubitemid 38850219)
30. Z Han, et al. 2007 Structural basis of EZH2 recognition by EED Structure 15 10 1306 1315 17937919 10.1016/j.str.2007.08.007 1:CAS:528:DC%2BD2sXhtFKhsLzE (Pubitemid 47539160)
31. F Tie, et al. 2007 The N terminus of Drosophila ESC binds directly to histone H3 and is required for E(Z)-dependent trimethylation of H3 lysine 27 Mol Cell Biol 27 6 2014 2026 17210640 10.1128/MCB.01822-06 1:CAS:528: DC%2BD2sXjsVSrsr4%3D (Pubitemid 46418460)
32. O Denisenko, et al. 1998 Point mutations in the WD40 domain of Eed block its interaction with Ezh2 Mol Cell Biol 18 10 5634 5642 9742080 1:CAS:528:DyaK1cXmsVKltbo%3D (Pubitemid 28450514)
33. R Margueron, et al. 2009 Role of the polycomb protein EED in the propagation of repressive histone marks Nature 461 7265 762 767 19767730 10.1038/nature08398 1:CAS:528:DC%2BD1MXhtFGjt73N
34. Xu C, et al. Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2). Proc Natl Acad Sci U S A. 107(45):19266-71.
35. K Yamamoto, et al. 2004 Polycomb group suppressor of zeste 12 links heterochromatin protein 1alpha and enhancer of zeste 2 J Biol Chem 279 1 401 406 14570930 10.1074/jbc.M307344200 1:CAS:528:DC%2BD3sXhtVSqt77J (Pubitemid 38044839)
36. K Sarma, et al. 2008 Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo Mol Cell Biol 28 8 2718 2731 18285464 10.1128/MCB.02017-07 1:CAS:528:DC%2BD1cXksFWqtrc%3D (Pubitemid 351542370)
37. F Tie, et al. 2001 The drosophila polycomb group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3 Development 128 2 275 286 11124122 1:CAS:528: DC%2BD3MXhtFCgtbY%3D (Pubitemid 32124152)
38. B Schuettengruber, et al. 2007 Genome regulation by polycomb and trithorax proteins Cell 128 4 735 745 17320510 10.1016/j.cell.2007.02.009 1:CAS:528:DC%2BD2sXis12isr8%3D (Pubitemid 46273581)
39. A Kuzmichev, et al. 2005 Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation Proc Natl Acad Sci USA 102 6 1859 1864 15684044 10.1073/pnas.0409875102 1:CAS:528: DC%2BD2MXhvFGrtLo%3D (Pubitemid 40261977)
40. A Kuzmichev, et al. 2004 Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3 Mol Cell 14 2 183 193 15099518 10.1016/S1097-2765(04)00185-6 1:CAS:528:DC%2BD2cXjvVyisb8%3D (Pubitemid 38515646)
41. R Margueron, et al. 2008 Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol Cell 32 4 503 518 19026781 10.1016/j.molcel. 2008.11.004 1:CAS:528:DC%2BD1cXhsVKgt7fP
42. Z Shao, et al. 1999 Stabilization of chromatin structure by PRC1, a Polycomb complex Cell 98 1 37 46 10412979 10.1016/S0092-8674(00)80604-2 1:CAS:528:DyaK1MXks1KksbY%3D (Pubitemid 29331194)
43. C Vincenz TK Kerppola 2008 Different polycomb group CBX family proteins associate with distinct regions of chromatin using nonhomologous protein sequences Proc Natl Acad Sci USA 105 43 16572 16577 18927235 10.1073/pnas.0805317105 1:CAS:528:DC%2BD1cXhtleksrjP
44. L Wang, et al. 2004 Hierarchical recruitment of polycomb group silencing complexes Mol Cell 14 5 637 646 15175158 10.1016/j.molcel.2004.05.009 1:CAS:528:DC%2BD2cXltlGnt7c%3D (Pubitemid 38739085)
45. R Cao Y Tsukada Y Zhang 2005 Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing Mol Cell 20 6 845 854 16359901 10.1016/j.molcel.2005.12.002 1:CAS:528:DC%2BD28XivVOjuw%3D%3D (Pubitemid 41814874)
46. H Wang, et al. 2004 Role of histone H2A ubiquitination in Polycomb silencing Nature 431 7010 873 878 15386022 10.1038/nature02985 1:CAS:528:DC%2BD2cXotl2ktrY%3D (Pubitemid 39434086)
47. W Zhou, et al. 2008 Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation Mol Cell 29 1 69 80 18206970 10.1016/j.molcel.2007.11.002
48. T Tonini, et al. 2004 Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A Oncogene 23 28 4930 4937 15077161 10.1038/sj.onc.1207608 1:CAS:528:DC%2BD2cXkvVOisr4%3D (Pubitemid 38932165)
49. Y Schlesinger, et al. 2007 Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer Nat Genet 39 2 232 236 17200670 10.1038/ng1950 1:CAS:528:DC%2BD2sXpvFertw%3D%3D (Pubitemid 46184355)
50. E Vire, et al. 2006 The Polycomb group protein EZH2 directly controls DNA methylation Nature 439 7078 871 874 16357870 10.1038/nature04431 1:CAS:528:DC%2BD28XhsVSkur0%3D (Pubitemid 43255707)
51. Y Kondo, et al. 2008 Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation Nat Genet 40 6 741 750 18488029 10.1038/ng.159 1:CAS:528:DC%2BD1cXmsVejtro%3D (Pubitemid 351748874)
52. NJ Francis, et al. 2001 Reconstitution of a functional core polycomb repressive complex Mol Cell 8 3 545 556 11583617 10.1016/S1097-2765(01)00316-1 1:CAS:528:DC%2BD3MXnslGmtr8%3D (Pubitemid 32946932)
53. GI Dellino, et al. 2004 Polycomb silencing blocks transcription initiation Mol Cell 13 6 887 893 15053881 10.1016/S1097-2765(04)00128-5 1:CAS:528:DC%2BD2cXjtFajs74%3D (Pubitemid 38438483)
54. A Sing, et al. 2009 A vertebrate Polycomb response element governs segmentation of the posterior hindbrain Cell 138 5 885 897 19737517 10.1016/j.cell.2009.08.020 1:CAS:528:DC%2BD1MXhsVCjs7%2FK
55. Woo CJ, et al. A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell. 140(1):99-110.
56. JL Brown, et al. 2003 The Drosophila pho-like gene encodes a YY1-related DNA binding protein that is redundant with pleiohomeotic in homeotic gene silencing Development 130 2 285 294 12466196 10.1242/dev.00204 1:CAS:528:DC%2BD3sXhtFaksLo%3D (Pubitemid 36175927)
57. Wilkinson F, Pratt H, Atchison ML. PcG recruitment by the YY1 REPO domain can be mediated by Yaf2. J Cell Biochem. 109(3):478-86.
58. Y Haupt, et al. 1991 Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice Cell 65 5 753 763 1904009 10.1016/0092-8674(91)90383-A 1:CAS:528: DyaK38XnslGnsQ%3D%3D (Pubitemid 121001307)
59. JJ Jacobs, et al. 1999 Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF Genes Dev 13 20 2678 2690 10541554 10.1101/gad.13.20.2678 1:CAS:528:DyaK1MXnt1Wqs7w%3D (Pubitemid 29508555)
60. FB Zhang LH Sui T Xin 2008 Correlation of Bmi-1 expression and telomerase activity in human ovarian cancer Br J Biomed Sci 65 4 172 177 19181034 1:CAS:528:DC%2BD1MXivVWguro%3D
61. ZK Qin, et al. 2009 Expression of Bmi-1 is a prognostic marker in bladder cancer BMC Cancer 9 61 19228380 10.1186/1471-2407-9-61
62. M Saeki, et al. 2009 Diagnostic importance of overexpression of Bmi-1 mRNA in early breast cancers Int J Oncol 35 3 511 515 19639171 1:CAS:528:DC%2BD1MXhtVOmtrfN
63. CG Kleer, et al. 2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci USA 100 20 11606 11611 14500907 10.1073/pnas.1933744100 1:CAS:528: DC%2BD3sXotFKmt7g%3D (Pubitemid 37205983)
64. S Varambally, et al. 2002 The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 6907 624 629 12374981 10.1038/nature01075 1:CAS:528:DC%2BD38Xns1Ontrk%3D
65. Bohrer LR, et al. Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology. 151(11):5136-45.
66. AP Bracken, et al. 2003 EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer EMBO J 22 20 5323 5335 14532106 10.1093/emboj/cdg542 1:CAS:528:DC%2BD3sXot1Cqsro%3D (Pubitemid 37279943)
67. Y Kotake, et al. 2007 pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene Genes Dev 21 1 49 54 17210787 10.1101/gad.1499407 1:CAS:528:DC%2BD2sXmsFyltw%3D%3D (Pubitemid 46089706)
68. B Shi, et al. 2007 Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells Mol Cell Biol 27 14 5105 5119 17502350 10.1128/MCB.00162-07 1:CAS:528:DC%2BD2sXotFamtbo%3D (Pubitemid 47068285)
69. X Tang, et al. 2004 Activated p53 suppresses the histone methyltransferase EZH2 gene Oncogene 23 34 5759 5769 15208672 10.1038/sj.onc.1207706 1:CAS:528:DC%2BD2cXmtVCns7g%3D (Pubitemid 39093021)
70. RJ Bryant, et al. 2007 EZH2 promotes proliferation and invasiveness of prostate cancer cells Prostate 67 5 547 556 17252556 10.1002/pros.20550 1:CAS:528:DC%2BD2sXlt1ahsrk%3D (Pubitemid 46536947)
71. Q Cao, et al. 2008 Repression of E-cadherin by the polycomb group protein EZH2 in cancer Oncogene 27 58 7274 7284 18806826 10.1038/onc.2008.333 1:CAS:528:DC%2BD1cXhsVylsb%2FM
72. S Fujii A Ochiai 2008 Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells Cancer Sci 99 4 738 746 18377425 10.1111/j.1349-7006.2008.00743.x 1:CAS:528: DC%2BD1cXlsFKmtbc%3D (Pubitemid 351448078)
73. Lu C, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 18(2):185-97.
74. M Zeidler CG Kleer 2006 The polycomb group protein enhancer of Zeste 2: its links to DNA repair and breast cancer J Mol Histol 37 5-7 219 223 16855786 10.1007/s10735-006-9042-9 1:CAS:528:DC%2BD28Xht1elsLjK (Pubitemid 44795625)
75. M Zeidler, et al. 2005 The polycomb group protein EZH2 impairs DNA repair in breast epithelial cells Neoplasia 7 11 1011 1019 16331887 10.1593/neo.05472 1:CAS:528:DC%2BD28XosVamsw%3D%3D
76. T Tonini, et al. 2008 Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements J Cell Physiol 214 2 295 300 17786943 10.1002/jcp.21241 1:CAS:528:DC%2BD1cXit10%3D (Pubitemid 350308984)
77. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 7(3):299-313.
78. L Jiang J Li L Song 2009 Bmi-1, stem cells and cancer Acta Biochim Biophys Sin (Shanghai) 41 7 527 534 10.1093/abbs/gmp040 1:CAS:528: DC%2BD1MXosVantL8%3D
79. TI Lee, et al. 2006 Control of developmental regulators by Polycomb in human embryonic stem cells Cell 125 2 301 313 16630818 10.1016/j.cell.2006.02. 043 1:CAS:528:DC%2BD28Xkt1Oqtbc%3D (Pubitemid 44313811)
80. AV Molofsky, et al. 2003 Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation Nature 425 6961 962 967 14574365 10.1038/nature02060 1:CAS:528:DC%2BD3sXosVOht7w%3D (Pubitemid 37376927)
81. JE Ohm, et al. 2007 A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing Nat Genet 39 2 237 242 17211412 10.1038/ng1972 1:CAS:528:DC%2BD2sXpvFeqsQ%3D%3D (Pubitemid 46184356)
82. C Martinez-Romero, et al. 2009 The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma J Pathol 219 2 205 213 19585519 10.1002/path.2585 1:CAS:528:DC%2BD1MXhtlSksb3O
83. SI Tschen, et al. 2009 Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice Diabetes 58 6 1312 1320 19228811 10.2337/db08-1651 1:CAS:528:DC%2BD1MXntFanurw%3D
84. S Dhawan SI Tschen A Bhushan 2009 Bmi-1 regulates the Ink4a/Arf locus to control pancreatic beta-cell proliferation Genes Dev 23 8 906 911 19390085 10.1101/gad.1742609 1:CAS:528:DC%2BD1MXlslSgtb0%3D
85. E Sangiorgi MR Capecchi 2009 Bmi1 lineage tracing identifies a self-renewing pancreatic acinar cell subpopulation capable of maintaining pancreatic organ homeostasis Proc Natl Acad Sci USA 106 17 7101 7106 19372370 10.1073/pnas.0902508106 1:CAS:528:DC%2BD1MXlvFSgt7s%3D
86. C Guerra, et al. 2007 Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice Cancer Cell 11 3 291 302 17349585 10.1016/j.ccr.2007.01.012 1:CAS:528:DC%2BD2sXjsVymtLs%3D (Pubitemid 46349841)
87. H Chen, et al. 2009 Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus Genes Dev 23 8 975 985 19390090 10.1101/gad.1742509 1:CAS:528:DC%2BD1MXlslSgtbc%3D
88. van Arensbergen J, et al. Derepression of Polycomb targets during pancreatic organogenesis allows insulin-producing beta-cells to adopt a neural gene activity program. Genome Res. 20(6):722-32.
89. MJ Gunster, et al. 2001 Differential expression of human Polycomb group proteins in various tissues and cell types J Cell Biochem Suppl Suppl 36 129 143 11455578 10.1002/jcb.1093 1:STN:280:DC%2BD3MvgtFSrtw%3D%3D (Pubitemid 32402052)
90. M Sanchez-Beato, et al. 2006 Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays Mod Pathol 19 5 684 694 16528373 10.1038/modpathol.3800577 1:CAS:528:DC%2BD28Xjs1agtbY%3D
91. Martínez-Romero C, et al. The epigenetic regulators Bmi1 and Ring1B are differentially regulated in pancreatitis and pancreatic ductal adenocarcinoma. J Pathol. 2009;205-13.
92. Song W, et al. Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci. 101(7):1754-60.
93. U Wellner, et al. 2009 The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs Nat Cell Biol 11 12 1487 1495 19935649 10.1038/ncb1998 1:CAS:528:DC%2BD1MXhsV2gsLnM
94. Y Li, et al. 2009 Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Cancer Res 69 16 6704 6712 19654291 10.1158/0008-5472.CAN-09-1298 1:CAS:528:DC%2BD1MXpvFejurc%3D
95. Karamitopoulou E, et al. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer. 46(8):1438-44.
96. I Bezsonova, et al. 2009 Ring1B contains a ubiquitin-like docking module for interaction with Cbx proteins Biochemistry 48 44 10542 10548 19791798 10.1021/bi901131u 1:CAS:528:DC%2BD1MXht1CgsbzJ
97. GN Maertens, et al. 2009 Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus PLoS ONE 4 7 e6380 19636380 10.1371/journal.pone.0006380
98. AV Ougolkov VN Bilim DD Billadeau 2008 Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2 Clin Cancer Res 14 21 6790 6796 18980972 10.1158/1078-0432.CCR-08-1013 1:CAS:528:DC%2BD1cXhtlens7jP
99. Chen Y, et al. RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic cancer in vivo. Cancer Lett. 297(1):109-16.
100. N Sato, et al. 2005 Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling Clin Cancer Res 11 13 4681 4688 16000561 10.1158/1078-0432.CCR-04-2471 1:CAS:528: DC%2BD2MXlvVGht7Y%3D (Pubitemid 41557185)
101. S Fujii, et al. 2008 Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation J Biol Chem 283 25 17324 17332 18430739 10.1074/jbc.M800224200 1:CAS:528:DC%2BD1cXntFSntb0%3D
102. M Wada, et al. 2004 Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines Oncogene 23 13 2401 2407 14743205 10.1038/sj.onc.1207395 1:CAS:528:DC%2BD2cXisVGksLs%3D (Pubitemid 38496795)
103. Toll AD, et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 41(9):1205-9.
104. JM Winter, et al. 2008 Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer Clin Cancer Res 14 2 412 418 18223216 10.1158/1078-0432.CCR-07-0487 1:CAS:528:DC%2BD1cXhtVKitL0%3D (Pubitemid 351226108)
105. Y Wei, et al. 2008 Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers Mol Carcinog 47 9 701 706 18176935 10.1002/mc.20413 1:CAS:528:DC%2BD1cXhtVCrsbnM
106. TL Cha, et al. 2005 Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3 Science 310 5746 306 310 16224021 10.1126/science.1118947 1:CAS:528:DC%2BD2MXhtV2hurvM (Pubitemid 41457195)
107. C Li, et al. 2007 Identification of pancreatic cancer stem cells Cancer Res 67 3 1030 1037 17283135 10.1158/0008-5472.CAN-06-2030 1:CAS:528: DC%2BD2sXht1yns70%3D
108. PC Hermann, et al. 2007 Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer Cell Stem Cell 1 3 313 323 18371365 10.1016/j.stem.2007.06.002 1:CAS:528: DC%2BD2sXhtFagu7vN (Pubitemid 47355323)
109. R Marechal, et al. 2009 High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma Br J Cancer 100 9 1444 1451 19352387 10.1038/sj.bjc.6605020 1:CAS:528:DC%2BD1MXltFGit7g%3D
110. Singh S, et al. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer. 103(11):1671-9.
111. Bayraktar S, Bayraktar UD, Rocha-Lima CM. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 16(6):673-82.
112. Shah AP, Strauss JB, Abrams RA. Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer. Am J Clin Oncol. 33(1):101-6.
113. J Tan, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, p. 1050-63 (Pubitemid 46686474)
114. TB Miranda, et al. 2009 DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation Mol Cancer Ther 8 6 1579 1588 19509260 10.1158/1535-7163.MCT-09-0013 1:CAS:528: DC%2BD1MXntVKgtr8%3D
115. DH Chen, et al. 2004 Effects of adenosine dialdehyde treatment on in vitro and in vivo stable protein methylation in HeLa cells J Biochem 136 3 371 376 15598895 10.1093/jb/mvh131 1:CAS:528:DC%2BD2cXhtFajtbrL (Pubitemid 39545798)
116. A Kirmizis, SM Bartley, PJ Farnham. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther. 2003. p. 113-21
117. Pizzatti L, et al. SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia. Genes Chromosomes Cancer 49(2):107-18.
118. S Liu, et al. 2006 Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells Cancer Res 66 12 6063 6071 16778178 10.1158/0008-5472.CAN-06-0054 1:CAS:528:DC%2BD28XlvVSksrY%3D
119. PS Rao, et al. 2009 RNF2 is the target for phosphorylation by the p38 MAPK and ERK signaling pathways Proteomics 9 10 2776 2787 19405034 10.1002/pmic.200800847 1:CAS:528:DC%2BD1MXmtlOmtL0%3D